ConductScience.org, home

Trial · NCT06726200

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200, Early phase 1, Recruiting, Rachel R. Luba

3 sourcestrials-2026-11-12-0.4.0

Download JSON
Cite this record

ConductScience Library. A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use. Trials, record NCT06726200. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06726200

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
NCT number
NCT06726200
Status
Recruiting
Phases
Early phase 1
Enrollment
60 participants, estimated
Lead sponsor
Rachel R. Luba
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
First posted
2024-12-10
Last updated
2026-06-02

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPercentage of Days Abstinent from Opioids4 week follow up periodAbstinence from Opioids (% days abstinent; continuous; longitudinal) during each week of the 4 week follow up period measured via the timeline follow back.
PrimarySustained Relapse4 week follow up periodSustained relapse during the 4 week follow up period (binary), defined as 5 consecutive days of illicit opioid use reported on the timeline follow back at any point during the 4 week follow up period.
SecondaryTime to Peak Clinical Opiate Withdrawal Scale (COWS) scoreDuring the inpatient induction period (approximately 1 overnight stay)
The time to peak Clinical Opiate Withdrawal Scale (COWS) score during the induction period (time-to-event/survival). The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.
SecondaryPeak Clinical Opiate Withdrawal Scale (COWS) scoreDuring the inpatient induction period (approximately 1 overnight stay)The peak Clinical Opiate Withdrawal Scale (COWS) score during the induction period (continuous). The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.
SecondaryDropout during inductionDuring the inpatient induction period (approximately 1 overnight stay)Dropout during the induction period (binary)
OtherExploratory Outcome 1: CravingInduction Period (Overnight Inpatient Stay) and 4-week follow up period
Craving as reported on the Opioid Craving Visual Analog Scale OC-VAS (longitudinal; continuous) during induction and follow up. The OC-VAS ranges from 0-100mm with higher ratings indicating more intense/severe craving.
OtherExploratory Outcome 2: Clinical Opiate Withdrawal Scale (COWS) ScoreInduction Period (Overnight Inpatient Stay) and 4-week follow up period
Opioid Withdrawal Symptoms as reported on the Clinical Opiate Withdrawal Scale (COWS; longitudinal; continuous) during induction and follow up. The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.
OtherExploratory Outcome 3: Time to first use of illicit opioids4-week follow up periodTime to first use of illicit opioids during the 4-week follow up period (time-to-event/survival)

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal years
K23DA057392A Randomized Controlled Trial Examining Extended-Injectable Buprenorphine in those who use High Potency Synthetic OpioidsLUBA, RACHEL RCOLUMBIA UNIVERSITY HEALTH SCIENCESNATIONAL INSTITUTE ON DRUG ABUSE2024 to 2025

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release
trials-2026-11-12-0.4.0
Release manifest SHA-256
0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture
2026-11-12
Results copy, AACT
2026-03-23
NIH clinical studies file
2026-11-13

Source ClinicalTrials.gov

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06726200

GET https://conductscience.org/api/trials/v1/NCT06726200/registered